PCM
GNMX

Prelude Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Prelude Capital Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-300
Closed – – 1874
2017
Q3 		$0 Buy
+300
New +$383 ﹤0.01% 2023

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Prelude Capital Management's GNMX Position: Q4 2017 in Review

Prelude Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 300 shares.

Prelude Capital Management first reported a position in GNMX in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • Prelude Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • Prelude Capital Management sold 300 Aevi Genomic Medicine Inc shares in Q4 2017.
  • Prelude Capital Management first reported a position in Aevi Genomic Medicine Inc in Q3 2017 and held it in 1 quarter.
  • Prelude Capital Management's Aevi Genomic Medicine Inc position peaked at $0 in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.